| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Ebenezer Tumban | |
| Lukai Zhai | |||
| Rashi Yadav | |||
| P2860 | cites work | Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate | Q24288709 |
| A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes | Q24537580 | ||
| Peptide Vaccine: Progress and Challenges | Q26851329 | ||
| Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions | Q27015709 | ||
| Structure and stability of icosahedral particles of a covalent coat protein dimer of bacteriophage MS2 | Q27655898 | ||
| Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice. | Q52312756 | ||
| Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen | Q59350469 | ||
| Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses | Q59358525 | ||
| A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine | Q63634603 | ||
| Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later – an exploratory study | Q64136236 | ||
| The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes | Q67686616 | ||
| Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes | Q73740013 | ||
| A Current Update on Human Papillomavirus-Associated Head and Neck Cancers | Q90632814 | ||
| Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity | Q92417124 | ||
| Evaluation of the thermal stability and the protective efficacy of spray-dried HPV vaccine, Gardasil® 9 | Q92441306 | ||
| Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer | Q92705318 | ||
| A rationally designed flagellin-L2 fusion protein induced serum and mucosal neutralizing antibodies against multiple HPV types | Q92858730 | ||
| Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines | Q28246307 | ||
| VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus | Q28280059 | ||
| Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes | Q28603888 | ||
| Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach | Q28607775 | ||
| A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2 | Q28741364 | ||
| A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women | Q30052389 | ||
| HPV vaccines - A review of the first decade | Q30234669 | ||
| Multi-epitope Models Explain How Pre-existing Antibodies Affect the Generation of Broadly Protective Responses to Influenza | Q30389700 | ||
| The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? | Q30425111 | ||
| Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection | Q30764287 | ||
| Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2 | Q33338311 | ||
| Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7 | Q33569555 | ||
| VLP-based vaccine induces immune control of Staphylococcus aureus virulence regulation | Q33677615 | ||
| Efficacy of Human Papillomavirus L1 Protein Vaccines (Cervarix and Gardasil) in Reducing the Risk of Cervical Intraepithelial Neoplasia: A Meta-analysis | Q33810515 | ||
| Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing | Q33967341 | ||
| Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection | Q34054427 | ||
| How B cells capture, process and present antigens: a crucial role for cell polarity | Q34353214 | ||
| Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. | Q34417608 | ||
| A cholesterol-lowering VLP vaccine that targets PCSK9 | Q34496015 | ||
| M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A. | Q34634610 | ||
| Durability of antibody response against hepatitis B virus in healthcare workers vaccinated as adults | Q35055166 | ||
| Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16 | Q35155333 | ||
| A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types | Q35196119 | ||
| The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine | Q35541210 | ||
| Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2 | Q35744303 | ||
| Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. | Q36314993 | ||
| Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model | Q36383391 | ||
| Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity | Q36483435 | ||
| Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. | Q36545925 | ||
| Arrangement of L2 within the papillomavirus capsid | Q36673336 | ||
| Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles | Q37073299 | ||
| L2, the minor capsid protein of papillomavirus | Q37164879 | ||
| A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants | Q37202927 | ||
| Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. | Q37306139 | ||
| Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic | Q37353496 | ||
| Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines | Q37356046 | ||
| The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding | Q37453403 | ||
| A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. | Q37604412 | ||
| Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns | Q37800358 | ||
| Construction and characterization of virus-like particles: a review | Q38045834 | ||
| Virus-induced humoral immunity: on how B cell responses are initiated | Q38111503 | ||
| Virus-like particles as vaccine | Q38255926 | ||
| Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies | Q38304498 | ||
| The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years | Q38383523 | ||
| The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years | Q38383530 | ||
| Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes | Q38640038 | ||
| The Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses : An Individual Participant Meta-analysis. | Q38785828 | ||
| Gardasil-9: A global survey of projected efficacy | Q38796961 | ||
| Biomedical and Catalytic Opportunities of Virus-Like Particles in Nanotechnology | Q39068831 | ||
| The effect of preexisting anti-carrier immunity on subsequent responses to CRM197 or Qb-VLP conjugate vaccines | Q39816694 | ||
| Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin | Q39860799 | ||
| Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes | Q39999319 | ||
| Cryoelectron Microscopy Maps of Human Papillomavirus 16 Reveal L2 Densities and Heparin Binding Site | Q40380856 | ||
| The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle. | Q40446848 | ||
| Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine | Q41110190 | ||
| Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector | Q41871491 | ||
| A novel candidate MS2 phage VLP vaccine displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9. | Q41931899 | ||
| Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells | Q42068510 | ||
| A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses | Q42229390 | ||
| Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial | Q42239419 | ||
| Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions | Q42625439 | ||
| Thermal stability of RNA phage virus-like particles displaying foreign peptides | Q42764128 | ||
| Virus like particles as a platform for cancer vaccine development. | Q45324534 | ||
| Transient expression of HPV16 E7 peptide (aa 44-60) and HPV16 L2 peptide (aa 108-120) on chimeric potyvirus-like particles using Potato virus X-based vector. | Q45399427 | ||
| Nanoparticles target distinct dendritic cell populations according to their size | Q45732404 | ||
| Subcellular Trafficking of the Papillomavirus Genome during Initial Infection: The Remarkable Abilities of Minor Capsid Protein L2. | Q47110116 | ||
| Broadly neutralizing antiviral responses induced by a single-molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope nanoparticles | Q47110564 | ||
| Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36. | Q47143249 | ||
| A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice | Q47194469 | ||
| Minor capsid protein L2 polytope induces broad protection against oncogenic and mucosal human papillomaviruses | Q47322093 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | capsid proteins | Q24779924 |
| Papillomavirus infections | Q104205912 | ||
| P577 | publication date | 2019-12-23 | |
| P1433 | published in | Viruses | Q7935305 |
| P1476 | title | Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today? | |
| P478 | volume | 12 |
Search more.